SCHEMBL5773045

SCHEMBL5773045

CNC(=O)C1(C)COC(c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)OC1

nearest known ligand 0.70

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 12/20 0.70
MAPK12 P53778 12/20 0.70
MAPK11 Q15759 12/20 0.70
MAPK14 Q16539 12/20 0.70
CSNK1A1 P48729 1/20 0.51
CSNK1D P48730 1/20 0.51
RPS6KA3 P51812 1/20 0.51
RAF1 P04049 2/20 0.50
MAPK9 P45984 2/20 0.50
SOAT1 P35610 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5770746 0.90 MAPK13 (0.67) MAPK13MAPK12MAPK11MAPK14CSNK1A1
SCHEMBL5771689 0.90 MAPK13 (0.70) MAPK13MAPK12MAPK11MAPK14CSNK1A1
SCHEMBL5770167 0.89 MAPK13 (0.74) MAPK13MAPK12MAPK11MAPK14CSNK1A1
SCHEMBL5769642 0.89 MAPK13 (0.74) MAPK13MAPK12MAPK11MAPK14CSNK1A1
SCHEMBL5772388 0.89 MAPK14 (0.70) MAPK13MAPK12MAPK11MAPK14CSNK1A1
SCHEMBL5769239 0.88 MAPK13 (0.73) MAPK13MAPK12MAPK11MAPK14CSNK1A1
SCHEMBL5773967 0.88 MAPK13 (0.65) MAPK13MAPK12MAPK11MAPK14CSNK1A1
SCHEMBL5770668 0.88 MAPK13 (0.65) MAPK13MAPK12MAPK11MAPK14CSNK1A1
SCHEMBL27545944 0.88 MAPK13 (0.65) MAPK13MAPK12MAPK11MAPK14CSNK1A1
SCHEMBL5767556 0.87 MAPK13 (0.64) MAPK13MAPK12MAPK11MAPK14CSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6989395-B2 Imidazolyl-cyclic acetals AVENTIS PHARMA LIMITED (GB) 2006-01-24 US claimed
US-20040038991-A1 Imidazolyl-cyclic acetals AVENTIS PHARMA LIMITED (GB) 2004-02-26 US claimed
EP-0988301-A1 IMIDAZOLYL-CYCLIC ACETALS RHONE-POULENC RORER LIMITED (GB) 2000-03-29 EP claimed
WO-1998056788-A1 IMIDAZOLYL-CYCLIC ACETALS RHONE-POULENC RORER LIMITED (GB) 1998-12-17 WO claimed
EP-0988301-B1 IMIDAZOLYL-CYCLIC ACETALS AVENTIS PHARMA LTD (GB) 2006-08-09 EP disclosed
US-6989395-B2 Imidazolyl-cyclic acetals AVENTIS PHARMA LIMITED (GB) 2006-01-24 US disclosed
US-20040038991-A1 Imidazolyl-cyclic acetals AVENTIS PHARMA LIMITED (GB) 2004-02-26 US disclosed
US-6602877-B1 Imidazolyl-cyclic acetals AVENTIS PHARMA LIMITED (GB) 2003-08-05 US disclosed
EP-0988301-A1 IMIDAZOLYL-CYCLIC ACETALS RHONE-POULENC RORER LIMITED (GB) 2000-03-29 EP disclosed
WO-1998056788-A1 IMIDAZOLYL-CYCLIC ACETALS RHONE-POULENC RORER LIMITED (GB) 1998-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038991-A1 Imidazolyl-cyclic acetals CBR1, LBR, CBR3 MAPK13 1610/4885MAPK12 2766/4885MAPK11 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.